patisiran (ONPATTRO) Report issue

Biologics Nucleic acid Orphan Drug FDA Approved FDA First in Class Fast Track FDA Priority Review FDA
AACT Drugs@FDA MeSH

Active Ingredient History

NOW
  • Now
Patisiran, sold under the brand name Onpattro, is a medication used for the treatment of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis, a fatal rare disease that is estimated to affect 50,000 people worldwide.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1410.0460 - $1871.3560
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

aln-ttr02 | patisiran | patisiran sodium

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (3)


 

Amyloid Neuropathies, Familial

Amyloidosis (approved 2018)

Polyneuropathies

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Amyloid Neuropathies (Phase 3)

Amyloid Neuropathies, Familial (Phase 3)

Amyloidosis (Phase 3)

Amyloidosis, Familial (Phase 3)

Cardiomyopathies (Phase 3)

Polyneuropathies (Early Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue